Related Experiment Video

Updated: Jul 7, 2026

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

[Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy

L Rinnab1, A Hessenauer, S V Schütz

  • 1Klinik für Urologie und Kinderurologie, Universität Ulm, Ulm, Germany. ludwig.rinnab@uniklinik-ulm.de

Der Urologe. Ausg. A
|February 15, 2008
PubMed

Insights

Hormone-refractory prostate cancer (PCA) progression is linked to androgen receptor (AR) expression, contrary to in vitro findings. New research identifies novel factors driving hormone-insensitive PCA, paving the way for advanced therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Context:

  • Advanced prostate cancer (PCA) exhibits high mortality rates, often driven by hormone-refractory progression.
  • In vitro studies suggest androgen receptor (AR) loss causes hormone insensitivity, but in vivo data indicate AR expression persists or increases.

Purpose:

  • To investigate the molecular mechanisms and identify new factors involved in the development of hormone-refractory prostate cancer.
  • To reconcile discrepancies between in vitro and in vivo observations regarding AR status in hormone-refractory PCA.

Summary:

  • Hormone-refractory prostate cancer (PCA) development is a critical factor in advanced disease progression and mortality.
  • While in vitro models implicate androgen receptor (AR) loss, in vivo studies reveal AR expression or overexpression in hormone-refractory PCA.
  • Cell and molecular studies have identified novel factors and mechanisms contributing to hormone-refractory tumor development.

Impact:

  • Findings challenge previous understandings of hormone-refractory PCA mechanisms.
  • Identified factors and mechanisms offer potential targets for new therapeutic strategies.
  • Advances understanding of PCA progression, potentially improving patient outcomes.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...